As TOP2A has been associated with response to anthracycline-based chemotherapy and aromatase inhibitors are widely used for breast cancer treatment, we explored if the expression of these genes and the intrinsic subtype of breast cancer could be associated with the development of recurrences. This evidence concerns the gene CYP19A1 and breast carcinoma.